ORIGINAL ARTICLE
Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study
Yan LanI, Shuo ZhouII, Weihong FengIII, Ying QiaoI, Xueming DuIII,
, Fenge LiIII,IV,
Corresponding author
Corresponding author
I Department of Oncology, Chifeng Songshan Hospital, Mongolia, China
II Department of Nuclear Medicine, Provincial Clinical Hospital of Fujian Medical University, Fuzhou, China
III Department of Oncology, Tianjin Beichen Hospital, Tianjin, China
IV Department of Melanoma, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Read
2362
Timeswas read the article
880
Total PDF
1482
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 64 | 94 | 158 |
| 2025 11 | 70 | 113 | 183 |
| 2025 10 | 37 | 50 | 87 |
| 2025 9 | 61 | 40 | 101 |
| 2025 8 | 72 | 37 | 109 |
| 2025 7 | 60 | 39 | 99 |
| 2025 6 | 23 | 9 | 32 |
| 2025 5 | 47 | 12 | 59 |
| 2025 4 | 48 | 11 | 59 |
| 2025 3 | 48 | 7 | 55 |
| 2025 2 | 38 | 6 | 44 |
| 2025 1 | 30 | 3 | 33 |
| 2024 12 | 28 | 4 | 32 |
| 2024 11 | 47 | 30 | 77 |
| 2024 10 | 37 | 25 | 62 |
| 2024 9 | 45 | 27 | 72 |
| 2024 8 | 56 | 29 | 85 |
| 2024 7 | 42 | 23 | 65 |
| 2024 6 | 37 | 12 | 49 |
| 2024 5 | 40 | 29 | 69 |
| 2024 4 | 66 | 33 | 99 |
| 2024 3 | 48 | 19 | 67 |
| 2024 2 | 31 | 19 | 50 |
| 2024 1 | 20 | 31 | 51 |
| 2023 12 | 27 | 15 | 42 |
| 2023 11 | 24 | 31 | 55 |
| 2023 10 | 22 | 43 | 65 |
| 2023 9 | 20 | 29 | 49 |
| 2023 8 | 32 | 7 | 39 |
| 2023 7 | 27 | 24 | 51 |
| 2023 6 | 27 | 4 | 31 |
| 2023 5 | 46 | 1 | 47 |
| 2023 4 | 53 | 8 | 61 |
| 2023 3 | 35 | 4 | 39 |
| 2023 2 | 26 | 3 | 29 |
| 2023 1 | 26 | 3 | 29 |
| 2022 12 | 14 | 4 | 18 |
| 2022 11 | 8 | 2 | 10 |
Show all
